SRTS - Sensus Healthcare's SRT-100 system shows promising results in treating mast cell tumors in pets study finds
2023-05-17 08:57:53 ET
-
- Sensus Healthcare ( NASDAQ: SRTS ) announces promising results in treating Cutaneous Mast Cell Tumors (MCTs) in pets using its SRT-100 system.
- Study published in the Journal of the American Veterinary Medical Association demonstrates effectiveness and safety of SRT treatment.
- Limited retrospective case series evaluated SRT as a non-invasive alternative for pets with MCT on the head.
- SRT treatment achieved a complete response in all cases that followed the intended protocol.
- No significant adverse events reported during the study.
- SRT-100 shows potential as a treatment option for MCTs in animals.
- Offers non-surgical alternative to surgery or chemotherapy.
- Study highlights minimal side effects associated with superficial radiation therapy for MCT treatment.
- SRT-100 could provide a viable option for veterinarians and pet owners dealing with MCTs in pets.
For further details see:
Sensus Healthcare's SRT-100 system shows promising results in treating mast cell tumors in pets, study finds